Market LIVE
Published markets; coverage varies by country
Product profile · United States

DOCETAXEL

 ·  Patent Litigation & Settlement History ↓

IngredientDOCETAXEL
Application typeNDA
Application215813
Product004
Dosage formINJECTABLE
RouteINJECTION
Strength160MG/16ML
Approval date2022-11-22
Marketing statusPrescription
Status event—
ApplicantAVYXA HOLDINGS
Product source

Current GenericRadar decision

Year2001
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeREGULATORY_EXCLUSIVITY
Anchor date2001-05-14
Patent anchor—
Exclusivity anchor2001-05-14
Protection date2036-03-14
First Final ANDA—
Status event—

POST_ANCHOR_PATENT_OR_EXCLUSIVITY_TAIL;BEST_EVIDENCE_SCOPE_ASSESSMENT

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
103987852036-03-14HISTORICAL_REFERENCE_SCOPE_REVIEWED —NNDP
English description not available.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
NCE1996-05-142001-05-14English description not available.YY2001-05-14—Source
I-2311998-06-222001-06-22Taxotere partial indication data; not full approved cancer scope.NN——Source
I-2821999-12-232002-12-23Taxotere NSCLC partial indication; historical tail after NCE2001-05-14.NN——Source

2026-10-13 · HISTORICAL_RECORDS_RECOVERED · Historical coverage: ANNUALS_AND_MONTHLY_REVIEWED

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Decision evidence (5)
TypeDateRoleBasisSource
PATENT2036-03-14FTO_TAILEnglish description not available.Source
REGULATORY_EXCLUSIVITY—SCOPE_CONTEXTTaxotere partial indication data; not full approved cancer scope.Source
REGULATORY_EXCLUSIVITY—SCOPE_CONTEXTTaxotere NSCLC partial indication; historical tail after NCE2001-05-14.Source
REGULATORY_EXCLUSIVITY2001-05-14CANONICAL_ANCHOREnglish description not available.Source
REGULATORY_STATUS2001-05-14CANONICAL_DECISIONPOST_ANCHOR_PATENT_OR_EXCLUSIVITY_TAIL;BEST_EVIDENCE_SCOPE_ASSESSMENTSource
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.